ES2091728A1 - Formulaciones de analogos de insulina monomericos. - Google Patents

Formulaciones de analogos de insulina monomericos.

Info

Publication number
ES2091728A1
ES2091728A1 ES09501196A ES9501196A ES2091728A1 ES 2091728 A1 ES2091728 A1 ES 2091728A1 ES 09501196 A ES09501196 A ES 09501196A ES 9501196 A ES9501196 A ES 9501196A ES 2091728 A1 ES2091728 A1 ES 2091728A1
Authority
ES
Spain
Prior art keywords
insulin analog
monomeric insulin
formulations
analog formulations
protamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09501196A
Other languages
English (en)
Other versions
ES2091728B1 (es
Inventor
Felippis Michael R De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2091728(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to ES9802174A priority Critical patent/ES2155752B1/es
Publication of ES2091728A1 publication Critical patent/ES2091728A1/es
Application granted granted Critical
Publication of ES2091728B1 publication Critical patent/ES2091728B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Abstract

FORMULACIONES DE ANALOGOS DE INSULINA MONOMERICOS. LA PRESENTE INVENCION DESCRIBE DIVERSAS FORMULACIONES FARMACEUTICAS PARENTERALES, QUE COMPRENDEN: UN ANALOGO DE INSULINA MONOMERICO, CINC, PROTAMINA Y UN DERIVADO FENOLICO. LAS FORMULACIONES DE ANALOGOS PROPORCIONAN UNA DURACION PROLONGADA DE LA ACTUACION. TAMBIEN SE DESCRIBE UN PROCEDIMIENTO PARA LA PREPARACION DE FORMULACIONES DE ANALOGO DE INSULINA-PROTAMINA.
ES09501196A 1994-06-16 1995-06-14 Formulaciones de analogos de insulina monomericos. Expired - Fee Related ES2091728B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9802174A ES2155752B1 (es) 1994-06-16 1995-06-14 Formulaciones de analogos de insulina monomericos.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,633 US5461031A (en) 1994-06-16 1994-06-16 Monomeric insulin analog formulations

Publications (2)

Publication Number Publication Date
ES2091728A1 true ES2091728A1 (es) 1996-11-01
ES2091728B1 ES2091728B1 (es) 1998-02-01

Family

ID=22989963

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09501196A Expired - Fee Related ES2091728B1 (es) 1994-06-16 1995-06-14 Formulaciones de analogos de insulina monomericos.

Country Status (37)

Country Link
US (3) US5461031A (es)
JP (1) JP3812962B2 (es)
KR (1) KR100386038B1 (es)
CN (1) CN1145641C (es)
AT (1) AT408611B (es)
BE (1) BE1009409A5 (es)
BR (1) BR9502797A (es)
CA (1) CA2151564C (es)
CH (2) CH693019A5 (es)
CO (1) CO4410204A1 (es)
CZ (1) CZ294556B6 (es)
DE (1) DE19521753B4 (es)
DK (1) DK176213B1 (es)
ES (1) ES2091728B1 (es)
FI (1) FI118208B (es)
FR (1) FR2721215B1 (es)
GB (1) GB2290294B (es)
GR (1) GR1002494B (es)
HU (1) HU218943B (es)
IE (1) IE68852B1 (es)
IL (1) IL114153A (es)
IT (1) IT1276722B1 (es)
LU (1) LU88627A1 (es)
MY (1) MY116831A (es)
NL (2) NL1000565C2 (es)
NO (1) NO320808B1 (es)
NZ (1) NZ272360A (es)
PE (1) PE34496A1 (es)
PL (1) PL183284B1 (es)
PT (1) PT101723B (es)
RO (1) RO115124B1 (es)
SE (1) SE509295C2 (es)
SI (1) SI9500199A (es)
TW (1) TW347334B (es)
UA (1) UA34468C2 (es)
YU (1) YU39795A (es)
ZA (1) ZA954941B (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
EP1607086A1 (en) * 1993-01-29 2005-12-21 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
EP0835129B1 (en) * 1995-06-30 2003-10-29 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
BR9709845B1 (pt) * 1996-06-20 2008-11-18 preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.
DE69829953T2 (de) * 1997-02-07 2006-03-02 Novo Nordisk A/S Kristallisation von proteinen
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
AR012894A1 (es) * 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
EP1283051B1 (en) * 1997-06-13 2006-06-14 Eli Lilly And Company Stable insulin formulations
PL340255A1 (en) * 1997-10-24 2001-01-29 Lilly Co Eli Non-dissolving insulin compositions
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
US20010053761A1 (en) * 1998-01-08 2001-12-20 Dimarchi Richard Dennis Method for administering aspb28-human insulin
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US6624141B1 (en) * 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
EP1346726A4 (en) * 2000-12-25 2004-09-15 Shiseido Co Ltd FRAGRANCE COMPOSITION STIMULATING THE SYMPATHETIC SYSTEM
EP1772464B1 (en) * 2001-02-09 2009-08-12 Genentech, Inc. Methods of identifying indirect agonists of IGF-1
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
CN1571676A (zh) * 2001-10-19 2005-01-26 伊莱利利公司 Glp－1和胰岛素的双相混合物
AU2002346491A1 (en) * 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
WO2004111244A2 (en) 2003-06-17 2004-12-23 Sembiosys Genetics Inc. Methods for the production of insulin in plants
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
JP2007520441A (ja) * 2003-07-25 2007-07-26 コンジュシェム，インコーポレイティド 持続性インスリン誘導体及びその方法
WO2005072803A1 (en) * 2004-01-16 2005-08-11 Biodel, Inc. Sublingual drug delivery device
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
PT2319500E (pt) * 2004-03-12 2013-01-23 Biodel Inc Composições de distribuição de fármacos de actuação rápida
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
WO2006014673A2 (en) 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AU2005273968A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7884181B2 (en) * 2004-10-05 2011-02-08 Novo Nordisk A/S Pharmaceutical formulation comprising crystalline insulin and dissolved insulin
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
CN100371346C (zh) * 2005-12-14 2008-02-27 浙江大学 人工合成胰岛素模拟肽及其应用
WO2007096431A1 (en) * 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US7718609B2 (en) * 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
CN101062948B (zh) * 2006-04-29 2010-05-12 上海生物泰生命科学研究有限公司 单体速效胰岛素及其制法和用途
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
ES2664822T3 (es) 2007-10-16 2018-04-23 Biocon Limited Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma
CN101951957A (zh) * 2008-01-04 2011-01-19 百达尔公司 胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂
WO2010028175A1 (en) 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
MA33064B1 (fr) * 2009-01-28 2012-02-01 Smartcells Inc Systemes à base de conjugués pour administration contrôlée de médicaments
MX2011008562A (es) 2009-02-12 2011-09-09 Proyecto Biomedicina Cima Sl Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabolicas.
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
HUP0900482A2 (en) * 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
AU2011282988A1 (en) 2010-07-28 2013-01-31 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
AU2011336896B2 (en) * 2010-11-24 2015-12-24 Durect Corporation Biodegradable drug delivery composition
US20140011733A1 (en) 2011-01-20 2014-01-09 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CA2890048C (en) 2012-12-03 2022-05-03 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
EP3052134B1 (en) 2013-10-04 2021-05-05 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
MX2016008978A (es) * 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
BR112016016290A2 (pt) 2014-01-13 2017-10-03 Thermalin Diabetes Llc Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
WO2017163159A1 (en) 2016-03-21 2017-09-28 Wockhardt Limited Biphasic pharmaceutical composition of insulin human
JP6633777B2 (ja) 2017-08-24 2020-01-22 ノヴォ ノルディスク アー／エス Ｇｌｐ−１組成物及びその使用
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
US11318191B2 (en) 2020-02-18 2022-05-03 Novo Nordisk A/S GLP-1 compositions and uses thereof
WO2021202802A1 (en) 2020-03-31 2021-10-07 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
PE20231948A1 (es) 2020-11-19 2023-12-05 Protomer Tech Inc Compuestos aromaticos que contienen boro y analogos de insulina
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) * 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
IE62879B1 (en) * 1987-02-25 1995-03-08 Novo Nordisk As Novel insulin derivatives
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
JPH03506023A (ja) * 1988-07-20 1991-12-26 ノボ　ノルデイスク　アクツイエセルスカプ ポリペプチド
AU641631B2 (en) * 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
DE10199011I2 (de) * 1993-06-21 2004-10-14 Novo Nordisk As ASP-B28-Insulinkristalle.
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRANGE, J. et al. "Chemical stability of insulin." ACTA. PHARM. NORD. 1992. Vol. 4, n‘ 3, pßginas 149-158 * Todo el documento * *
BREMS, D.N. et al. "Altering the association properties of insulin by amino acid replacement." PROTEIN ENGINEERING. 1992. Vol. 5, n‘ 6, pßginas 527-533 * Todo el documento * *
DEREWENDA, U. et al. "Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer." NATURE. 1989. Vol. 338, pßginas 594-596 * Todo el documento * *

Also Published As

Publication number Publication date
FI952932A (fi) 1995-12-17
GB2290294B (en) 1999-03-17
SE9502168D0 (sv) 1995-06-14
US5461031A (en) 1995-10-24
IL114153A (en) 2000-09-28
PT101723A (pt) 1995-12-29
US5650486A (en) 1997-07-22
NO952356D0 (no) 1995-06-14
FI118208B (fi) 2007-08-31
KR960000923A (ko) 1996-01-25
CH693019A5 (de) 2003-01-31
NO320808B1 (no) 2006-01-30
CA2151564C (en) 2003-02-11
NL1000565A1 (nl) 1995-12-18
HU9501717D0 (en) 1995-08-28
IL114153A0 (en) 1995-10-31
GB9512105D0 (en) 1995-08-09
MY116831A (en) 2004-04-30
YU39795A (sh) 1998-05-15
DK176213B1 (da) 2007-02-12
ZA954941B (en) 1996-12-17
BE1009409A5 (fr) 1997-03-04
BR9502797A (pt) 1996-03-12
PT101723B (pt) 1997-02-28
NL1004643C2 (nl) 1997-02-12
UA34468C2 (uk) 2001-03-15
DK67695A (da) 1995-12-17
NZ272360A (en) 1997-02-24
SE509295C2 (sv) 1999-01-11
JPH083064A (ja) 1996-01-09
RO115124B1 (ro) 1999-11-30
FR2721215B1 (fr) 1997-08-14
NO952356L (no) 1995-12-18
SI9500199A (en) 1996-02-29
CA2151564A1 (en) 1995-12-17
CZ154395A3 (en) 1996-02-14
CO4410204A1 (es) 1997-01-09
CZ294556B6 (cs) 2005-02-16
AT408611B (de) 2002-01-25
ES2091728B1 (es) 1998-02-01
SE9502168L (sv) 1995-12-17
CN1116629A (zh) 1996-02-14
IE68852B1 (en) 1996-07-24
DE19521753B4 (de) 2009-07-23
US5747642A (en) 1998-05-05
LU88627A1 (fr) 1996-02-01
IE950435A1 (en) 1995-12-27
GB2290294A (en) 1995-12-20
PE34496A1 (es) 1996-10-01
PL183284B1 (pl) 2002-06-28
ATA101795A (de) 2001-06-15
DE19521753A1 (de) 1995-12-21
HUT71908A (en) 1996-02-28
GR1002494B (el) 1996-12-12
FR2721215A1 (fr) 1995-12-22
NL1004643A1 (nl) 1996-12-17
IT1276722B1 (it) 1997-11-03
ITMI951277A0 (it) 1995-06-14
ITMI951277A1 (it) 1996-12-14
TW347334B (en) 1998-12-11
PL309100A1 (en) 1995-12-27
NL1000565C2 (nl) 1996-12-03
HU218943B (hu) 2001-01-29
FI952932A0 (fi) 1995-06-14
JP3812962B2 (ja) 2006-08-23
CH689934A5 (de) 2000-02-15
CN1145641C (zh) 2004-04-14
KR100386038B1 (ko) 2003-08-27

Similar Documents

Publication Publication Date Title
MY116831A (en) Monomeric insulin analog formulations
EP1090640A3 (en) Insulin analog formulations
MY121543A (en) Preparation of 3,4,4-trisubstituted-piperidinyl-n- alkylcarboxylates and intermediates
ZA962502B (en) Monomeric insulin analog formulations.
GR950100229A (en) Insulin analog formulations.
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
UA32543C2 (uk) Арилацетаміди, що мають анальгетичну дію, спосіб їх одержання, фармацевтична композиція та спосіб її одержання
ZA969820B (en) Fluorinated or hydroxylated phenylimidazolidines, preparation process and intermediates, use as medicaments, new use and pharmaceutical compositions.
SG93791A1 (en) Synthetic polynucleotides
CS29990A3 (en) Racemic or optically active bis-aza-bicyclic compounds, process forpreparing thereof, intermediates and use
AU1539592A (en) Retainer assembly for syringe tip
AU674378B2 (en) Use of 2-amino-6-A-propylamino-4,5,6, 7-tetrahydrobenzothiazole (pramipexol) as an anti-depressantdrug
AU6664290A (en) Flexible spray tip for syringe
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
ZA929879B (en) Compositions for the treatment of mammalian diseases.
EP0597130A4 (en) Antirheumatic.
IE820987L (en) Esters of n-substituted amino acids
AU2168295A (en) Monomeric insulin analog formulations
EP0594481A3 (en) Medium movement articulator capable of being adjusted for free movement.
AU738101C (en) Monomeric insulin analog formulations
EP0649847A3 (en) Processes and intermediates for the production of (+) - hydantocidin and its analogues.
HU896157D0 (en) Acupunctural needle, particularly for long-time acupunctural treatment
AU2413288A (en) Improved metal nozzle
GB9827008D0 (en) Monomeric insulin analog formulations

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19961101

Kind code of ref document: A1

Effective date: 19961101

FD2A Announcement of lapse in spain

Effective date: 20150925